"シオノギ製薬" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonNotice of Head Office Relocation｜ 塩野義製薬 - Shionogi
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - GlobeNewswire
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia GlobeNewswire
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters.com
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission Reuters.com
David Benadon｜ 塩野義製薬 - Shionogi
David Benadon｜ 塩野義製薬 Shionogi
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement f...
Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter
Nxera and Shionogi launch Quviviq in Japan The Pharma Letter
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - EURA...
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO EURACTIV
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan - Sleep Review
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan Sleep Review
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego - Genetic Engineering & Biotechnology News
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego Genetic Engineering & Biotechnology News
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 - Shionogi
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 Shionogi
Antibiotics, an important but tricky business, says Shionogi CEO - EURACTIV
Antibiotics, an important but tricky business, says Shionogi CEO EURACTIV
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter - The Pharma Letter
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter The Pharma Letter
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
“Pharmaceutical Education” by Virtual Employee｜ SHIONOGI - Shionogi
“Pharmaceutical Education” by Virtual Employee｜ SHIONOGI Shionogi
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadersh...
Striving for Palliative Care that Leaves No One Behind: Aiming for a Communication Barrier-Free R...
Dialogue 2021｜シオノギ製薬（塩野義製薬） - Shionogi
Dialogue 2021｜シオノギ製薬（塩野義製薬） Shionogi
Shionogi's antiviral comes up short in global COVID-19 trial - FiercePharma
Shionogi's antiviral comes up short in global COVID-19 trial FiercePharma
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment Precedence Research
Maze lands new partner for Pompe drug, after Sanofi pact came apart - BioPharma Dive
Maze lands new partner for Pompe drug, after Sanofi pact came apart BioPharma Dive
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment The Hearing Review
Insomnia drug launched by Nxera Pharma and Shionogi & Co - Cambridge Independent
Insomnia drug launched by Nxera Pharma and Shionogi & Co Cambridge Independent
Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next - Si...
Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next Simply Wall St
Keiko Tone - Shionogi - Board Member - The Association of the British Pharmaceutical Industry
Keiko Tone - Shionogi - Board Member The Association of the British Pharmaceutical Industry
Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic Nikkei Asia
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill - Nikkei Asia
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill Nikkei Asia
Global study shows cefiderocol’s success in treating resistant infections - European Pharmaceutic...
Global study shows cefiderocol’s success in treating resistant infections European Pharmaceutical Manufacturer
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health
Margaret Borys - Shionogi
Margaret Borys Shionogi
Medium-Term Business Plan STS2030 Revision（FY2023 – FY2030） | Business Strategy | Shionogi & Co...
Address the problem of antimicrobial resistance (AMR) - Shionogi
Address the problem of antimicrobial resistance (AMR) Shionogi
Mother to Mother SHIONOGI Project - Shionogi
Mother to Mother SHIONOGI Project Shionogi
Message from Top Management - Shionogi
Message from Top Management Shionogi
History - Shionogi
History Shionogi
Nathan McCutcheon - Shionogi
Nathan McCutcheon Shionogi
Tadashi Hara - Shionogi
Tadashi Hara Shionogi
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for...
Partnering to Bring Meaningful Science to Patients - Shionogi
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat - ...
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat Nature.com
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters.com
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters.com
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean spor...
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean sport WADA
Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Hea...
Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam Business Wire
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex ...
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc. Business Wire
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline BioSpace
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval - Reuters.com
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval Reuters.com
Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology
Shionogi to acquire Qpex Biopharma for $140m Pharmaceutical Technology
Shionogi Strengthens U.S. Executive Leadership Team to Support Growth - Business Wire
Shionogi Strengthens U.S. Executive Leadership Team to Support Growth Business Wire
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine Fierce Biotech
Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against B...
Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against BeiGene FiercePharma
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commerc...
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization Business Wire
Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter
Shionogi’s ensitrelvir prevents symptomatic COVID-19 The Pharma Letter
Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld Online
Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld Online
Shionogi takes Akili’s ADHD digital therapy to Japan - pharmaphorum
Shionogi takes Akili’s ADHD digital therapy to Japan pharmaphorum
F2G enlists Shionogi to bring antifungal treatment to Europe and Asia - Labiotech.eu
F2G enlists Shionogi to bring antifungal treatment to Europe and Asia Labiotech.eu
Shionogi Announces Agreement With SOBI - European Pharmaceutical Manufacturer
Shionogi Announces Agreement With SOBI European Pharmaceutical Manufacturer
Shionogi Second Quarter 2025 Earnings: Revenues Beat Expectations - Simply Wall St
Shionogi Second Quarter 2025 Earnings: Revenues Beat Expectations Simply Wall St
Shionogi’s oral COVID-19 antiviral wins full approval in Japan - BioWorld Online
Shionogi’s oral COVID-19 antiviral wins full approval in Japan BioWorld Online
Shionogi agrees $140m deal to buy antibiotic biotech Qpex - pharmaphorum
Shionogi agrees $140m deal to buy antibiotic biotech Qpex pharmaphorum
Shionogi launches novel antibiotic Fetcroja in the UK - PharmaTimes
Shionogi launches novel antibiotic Fetcroja in the UK PharmaTimes
Japan grants emergency regulatory approval for Shionogi’s Covid-19 drug - Pharmaceutical Technology
Japan grants emergency regulatory approval for Shionogi’s Covid-19 drug Pharmaceutical Technology
In global access push, Orchid Pharma gains license to manufacture the antibiotic cefiderocol - Fi...
In global access push, Orchid Pharma gains license to manufacture the antibiotic cefiderocol FiercePharma
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression - BioWorld Online
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression BioWorld Online
3 Firms Advise Pharmas On $150M Joint Venture - Law360
Shionogi seeks to break away from China for COVID drug materials - Nikkei Asia
Shionogi seeks to break away from China for COVID drug materials Nikkei Asia
Shionogi and Daiichi Sankyo join hunt for omicron vaccine - Nikkei Asia
Shionogi and Daiichi Sankyo join hunt for omicron vaccine Nikkei Asia
Shionogi launches cheaper rival to Dova’s Doptelet - BioPharma Dive
Shionogi launches cheaper rival to Dova’s Doptelet BioPharma Dive
Drugmaker Shionogi inks deal to market COVID pill in China - Nikkei Asia
Drugmaker Shionogi inks deal to market COVID pill in China Nikkei Asia
Shionogi leads Japan's push for homegrown vaccines - Nikkei Asia
Shionogi leads Japan's push for homegrown vaccines Nikkei Asia
Mulpleta FDA nod in hand, Shionogi must distinguish it from competitor Dova's similar drug - Fier...
Mulpleta FDA nod in hand, Shionogi must distinguish it from competitor Dova's similar drug FiercePharma
FDA approves Shionogi's antibiotic Fetroja with spooky mortality warning label - FiercePharma
FDA approves Shionogi's antibiotic Fetroja with spooky mortality warning label FiercePharma
Digital therapeutics startup Akili Interactive inks deal with Japanese pharma company - MedCity News
Digital therapeutics startup Akili Interactive inks deal with Japanese pharma company MedCity News
Promising new data for Shionogi's S-217622, a therapeutic drug for COVID-19 - The Pharma Letter
Promising new data for Shionogi's S-217622, a therapeutic drug for COVID-19 The Pharma Letter
Japan's Shionogi bucks the pharma trend with focus on old, cheap drugs - FiercePharma
Japan's Shionogi bucks the pharma trend with focus on old, cheap drugs FiercePharma
Shionogi's new COVID pill appears to ease omicron symptoms - Nikkei Asia
Shionogi's new COVID pill appears to ease omicron symptoms Nikkei Asia
Elix and Shionogi partner to validate retrosynthetic analysis model to discover drugs - BioWorld ...
Elix and Shionogi partner to validate retrosynthetic analysis model to discover drugs BioWorld Online
F2G out-licenses rights to new antifungal agent olorofim - The Pharma Letter
F2G out-licenses rights to new antifungal agent olorofim The Pharma Letter
Dova prepares for newly minted Doptelet launch, with Shionogi’s rival close behind - FiercePharma
Dova prepares for newly minted Doptelet launch, with Shionogi’s rival close behind FiercePharma
Shionogi out-licenses assets in China - The Pharma Letter
Shionogi out-licenses assets in China The Pharma Letter
Pharmaceutical maker Shionogi tapping AI to speed drug development - Nikkei Asia
Pharmaceutical maker Shionogi tapping AI to speed drug development Nikkei Asia
Shionogi’s FETROJA now available for treatment of complicated urinary tract infections in US - Ph...
Shionogi’s FETROJA now available for treatment of complicated urinary tract infections in US Pharmaceutical Business Review
Japanese pharma firm Shionogi launches anti-bacterial drug in Denmark - BSA bureau
Japanese pharma firm Shionogi launches anti-bacterial drug in Denmark BSA bureau
Shionogi eases its way into the consumer space - MM+M Online
Shionogi eases its way into the consumer space MM+M Online
Shionogi says non-clinical trial results will not affect Covid-19 drug approval - KBR
Shionogi says non-clinical trial results will not affect Covid-19 drug approval KBR
Lupin acquires 21 branded products from Japan's Shionogi for $ 150 mn - Business Standard
Lupin acquires 21 branded products from Japan's Shionogi for $ 150 mn Business Standard
Shire, Shionogi in Strategic ADHD Pact - Contract Pharma
Shire, Shionogi in Strategic ADHD Pact Contract Pharma
Lupin to buy 21 products for Rs 1,000 cr from Japan’s Shionogi - Hindustan Times
Lupin to buy 21 products for Rs 1,000 cr from Japan’s Shionogi Hindustan Times
Shionogi Bids To Acquire Sciele Pharma - Contract Pharma
Shionogi Bids To Acquire Sciele Pharma Contract Pharma